|Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH||Chief Exec. Officer, Managing Director and Exec. Director||5.43M||N/A||60|
|Mr. John Miller||Interim CFO & Sr. VP of Fin.||N/A||N/A||N/A|
|Mr. Matthew Walker BSCHE||Head of Technical Operations||N/A||N/A||54|
|Prof. Andreas Busch||Head of R&D, Chief Scientific Officer & Exec. VP||N/A||N/A||55|
|Mr. William Richard Mordan||Gen. Counsel & Corp. Sec.||N/A||N/A||48|
Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; SFJ Pharmaceuticals Group; and Rani Therapeutics. Shire plc was founded in 1986 and is based in Dublin, Ireland.
Shire plc’s ISS governance QualityScore as of 1 January 2018 is 4. The pillar scores are Audit: 9; Board: 1; Shareholder rights: 1; Compensation: 1.